While more biosimilars gained regulatory approval 2017 and neared their entry into the US marketplace, physician acceptance of these products proved to be a challenge.
While more biosimilars gained regulatory approval in 2017 and neared their entry into the US marketplace, physician acceptance of these products proved to be a challenge.
A survey of community-based US oncologists and hematologists found that:
The researchers in this study concluded that significant gaps in education pose a barrier to physicians’ acceptance of oncology biosimilars, and 2 posters presented at the American College of Rheumatology’s 2017 meeting in San Diego, California, pointed to similar gaps in US rheumatologists’ knowledge.
In the first, a survey of practicing rheumatologists, approximately 60% of respondents were unlikely to switch from a reference biologic to a biosimilar in patients who were responding well to their current therapy. Additionally, 21% of respondents were extremely likely or likely to switch to a biosimilar if the patient was failing to respond well to the originator.
In the second survey, in which respondents were rheumatologists or rheumatology practice managers, only 51% understood the concept of interchangeability, only 40% believed that biosimilars had equivalent safety and efficacy to their references, and 20% said they would not prescribe a biosimilar.
The results of such surveys led Stacie Phan, MBA, MS, president of the Biosimilars Forum, to write in a contributor article at The Center for Biosimilars® that “Researchers who worked on both surveys concluded that physicians’ lack of knowledge about biosimilars and their ambivalence about prescribing these drugs present a significant barrier for building a robust biosimilars market in the United States. This barrier has implications not only for patients suffering from RA, but also from psoriatic arthritis, Crohn disease, ulcerative colitis, and various types of cancer—including breast cancer, metastatic colorectal cancer, non-squamous non-small cell lung cancer, and glioblastoma.”
Phan called for physicians to educate themselves about these therapies for the good of their patients: “We need a medical community that is fully educated about the benefits of biosimilars so that the promise of these drugs can be fully realized in the United States,” she said.
How State Substitution Laws Shape Insulin Biosimilar Adoption
April 15th 2025States with fewer restrictions on biosimilar substitution tend to see higher uptake of interchangeable insulin glargine, showing how even small policy details can significantly influence biosimilar adoption and expand access to more affordable insulin.
How AI Can Help Address Cost-Related Nonadherence to Biologic, Biosimilar Treatment
March 9th 2025Despite saving billions, biosimilars still account for only a small share of the biologics market—what's standing in the way of broader adoption and how can artificial intelligence (AI) help change that?
Patients With IBD Maintain Therapy 2 Years Post Switching to Infliximab Biosimilar
March 23rd 2025People with inflammatory bowel disease (IBD) who switched to the infliximab biosimilar CT-P13 had higher treatment persistence (84% and 91%) than those new to infliximab (66% and 53%), with no new safety concerns.
Will the FTC Be More PBM-Friendly Under a Second Trump Administration?
February 23rd 2025On this episode of Not So Different, we explore the Federal Trade Commission’s (FTC) second interim report on pharmacy benefit managers (PBMs) with Joe Wisniewski from Turquoise Health, discussing key issues like preferential reimbursement, drug pricing transparency, biosimilars, shifting regulations, and how a second Trump administration could reshape PBM practices.
How Vertical Integration Drives Innovation and Access in Biosimilars
December 27th 2024Elie Bahou, PharmD, highlights how vertical integration in the biosimilar industry streamlines costs, improves supply reliability, accelerates market adoption, and enhances patient access, while emphasizing the value of collaboration, quality control, and value-based contracts for sustainable health care delivery.
Empowering Vulnerable Populations: The Path to Equitable Biologic Therapy Access
December 22nd 2024Elie Bahou, PharmD, senior vice president and system chief pharmacy officer at Providence, discusses strategies to improve equitable access to biologic therapies, including tiered formularies, income-based cost sharing, patient assistance programs, and fostering payer partnerships.